Evidence map›Paper›PMID 38256107›Full record

ArticleInternational journal of molecular sciences2024

Targeting Alzheimer's Disease: Evaluating the Efficacy of C-1 Functionalized N-Aryl-Tetrahydroisoquinolines as Cholinergic Enzyme Inhibitors and Promising Therapeutic Candidates.

Dunja Jovanović, Ana Filipović, Goran Janjić, Tamara Lazarević-Pašti, Zdravko Džambaski, Bojan P Bondžić, Aleksandra M Bondžić

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dunja JovanovićVinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, P.O. Box 522, 11000 Belgrade, Serbia.ORCID 0000-0002-9459-8271
Ana FilipovićInstitute of Chemistry, Technology and Metallurgy, National Institute of the Republic of Serbia, University of Belgrade, Njegoševa 12, 11000 Belgrade, Serbia.
Goran JanjićInstitute of Chemistry, Technology and Metallurgy, National Institute of the Republic of Serbia, University of Belgrade, Njegoševa 12, 11000 Belgrade, Serbia.
Tamara Lazarević-PaštiVinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, P.O. Box 522, 11000 Belgrade, Serbia.ORCID 0000-0001-6220-2079
Zdravko DžambaskiInstitute of Chemistry, Technology and Metallurgy, National Institute of the Republic of Serbia, University of Belgrade, Njegoševa 12, 11000 Belgrade, Serbia.
Bojan P BondžićInstitute of Chemistry, Technology and Metallurgy, National Institute of the Republic of Serbia, University of Belgrade, Njegoševa 12, 11000 Belgrade, Serbia.
Aleksandra M BondžićVinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, P.O. Box 522, 11000 Belgrade, Serbia.ORCID 0000-0002-7403-2318

Funding

the Ministry of Science, Technological Development, and Innovation of the Republic of Serbia 451-03-47/2023-01/200017 and 451-03-47/2023-01/200026
6 · The paper itself

Abstract

We have synthesized 22 C-1 functionalized-

Indexed as

Alzheimer DiseaseTetrahydroisoquinolinesButyrylcholinesteraseEnzyme InhibitorsHumansKineticsMolecular Docking SimulationButyrylcholinesteraseEnzyme InhibitorsTetrahydroisoquinolinesacetylcholinesteraseAlzheimer’s diseasebutyrylcholinesterasetetrahydroisoquinolines

Identifiers

PMID38256107
PMCPMC10816625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.